ArticleEmerging infectious diseases2025
Prolonged Monkeypox Virus Infections, California, USA, May 2022-August 2024.
Article in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Monkeypox virus (MPXV) infection typically lasts 14-28 days. Prolonged MPXV infection, in which symptoms or test positivity last >28 days, has been documented but not fully characterized. We used the California Department of Public Health (California, USA) mpox registry to compare prolonged (>28 days) and nonprolonged (<28 days) mpox cases by demographics, HIV status, and JYNNEOS vaccination status. Of 6,469 cases, 82 (1.3%) were prolonged. Persons with prolonged MPXV infections were more likely to be Black or African American (prolonged, 20.7%, vs. nonprolonged, 11.6%) and to have HIV (prolonged, 61.0%, vs. nonprolonged, 39.9%). Among persons with HIV, prolonged infections were more likely among those with lower (<200) CD4 counts (prolonged, 10.0%, vs. nonprolonged, 3.9%) or not engaged in HIV care (prolonged, 46.0%, vs. nonprolonged, 18.1%). No prolonged infections occurred in persons who received 2 JYNNEOS vaccine doses. Groups disproportionately affected by prolonged mpox should be prioritized for mpox vaccine education and outreach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.